Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Once-Daily Oral JAK Inhibitor for Atopic Dermatitis Effective in Phase 3 Study

Key clinical point: The investigational, once-daily oral Janus kinase 1 inhibitor abrocitinib met all primary and secondary endpoints in a pivotal phase 3 trial.

Major finding: An Eczema Area and Severity Index–75 response rate was achieved at week 12 in 63% of atopic patients on oral abrocitinib monotherapy at 200 mg once daily, 40% on 100 mg, and 12% on placebo, with a statistically significant separation from placebo by week 2 for both doses.

Study details: This was a pivotal phase 3, double-blind, randomized trial including 387 adolescents and adults with moderate or severe atopic dermatitis.

Disclosures: The presenter reported receiving research grants from and serving as a consultant to Pfizer, the study sponsor, as well as having financial relationships with roughly a dozen other pharmaceutical companies.

Citation:

Simpson E. EADV late breaker.